|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 91, 647-661, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
GT Christakis, SE Fremes, RD Weisel, JG Tittley, DA Mickle, J Ivanov, MM Madonik, AM Benak, PR McLaughlin and RJ Baird
Calcium channel blockers may prevent myocardial injury during cardioplegia
and reperfusion. A prospective, randomized trial was instituted to evaluate
the hemodynamic and myocardial metabolic recovery in 40 patients undergoing
elective aorta-coronary bypass with either diltiazem in crystalloid
potassium cardioplegia (n = 20) or crystalloid potassium cardioplegia (n =
20). In a preliminary trial, doses between 150 and 250 micrograms/kg
reduced the period of heart block after cross-clamp removal (90 +/- 110
minutes) from that found with higher doses and improved myocardial
metabolism. In the randomized trial, diltiazem cardioplegia (150
micrograms/kg) produced coronary vasodilatation during cardioplegia and
produced less reactive hyperemia during reperfusion. Myocardial oxygen
extraction was lower and myocardial lactate production was less after
diltiazem cardioplegia during reperfusion. Tissue adenosine triphosphate
and creatine phosphate concentrations were preserved better after diltiazem
cardioplegia. The postoperative creatine kinase MB levels were less (p less
than 0.05) after diltiazem cardioplegia, which indicated less myocardial
injury. Postoperative volume loading demonstrated that systolic function
(the relation between systolic blood pressure and end- systolic volume
index) was depressed after diltiazem cardioplegia compared to crystalloid
cardioplegia, but cardiac index was higher because afterload (mean arterial
pressure) was lower and preload (end- diastolic volume index) was higher.
Diltiazem cardioplegia preserved high-energy phosphates, improved
postoperative myocardial metabolism, and reduced ischemic injury after
elective coronary bypass. However, diltiazem was a potent negative inotrope
and produced prolonged periods of electromechanical arrest. Diltiazem
cardioplegia may be of value in patients with severe ischemia but should be
used with caution in patients with ventricular dysfunction, and a
dose-response relation must be established at each institution before
clinical use.
ARTICLES
Diltiazem cardioplegia. A balance of risk and benefit
This article has been cited by other articles:
![]() |
D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dagenais, R. Cartier, C. Hollmann, and J. Buluran Calcium-Channel Blockers Preserve Coronary Endothelial Reactivity After Ischemia-Reperfusion Ann. Thorac. Surg., April 1, 1997; 63(4): 1050 - 1056. [Abstract] [Full Text] |
||||
![]() |
U. Acikel, E. Hazan, N. Sariosmanoglu, H. Catalyurek, E. Silistreli, G. Guner, N. Saydam, Y. Tuncok, H. Guven, O. Karabay, et al. Nisoldipine Cardioplegia in the Isolated Rabbit Heart Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 285 - 290. [Abstract] [PDF] |
||||
![]() |
J. C. Cleveland Jr, D. R. Meldrum, R. T. Rowland, A. Banerjee, and A. H. Harken Optimal Myocardial Preservation: Cooling, Cardioplegia, and Conditioning Ann. Thorac. Surg., February 1, 1996; 61(2): 760 - 768. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |